| Q51590258 | 17 beta-Estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate. |
| Q37197085 | A comparative study of lipid profile and oestradiol in pre- and post-menopausal women |
| Q73388160 | A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17beta-estradiol on lipid and lipoprotein profiles |
| Q46741146 | A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. |
| Q51386266 | APOE -491 T allele may reduce the risk of atherosclerotic lesions among middle-aged women. |
| Q46029229 | An open-label study of subdermal implants of estradiol-only versus subdermal implants of estradiol plus nomegestrol acetate: effects on symptom control, lipid profile and tolerability. |
| Q41529350 | Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. |
| Q78067776 | Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals |
| Q33684739 | Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure |
| Q50859074 | Blood pressure, plasma NPY and catecholamines during physical exercise in relation to menstrual cycle, ovariectomy, and estrogen replacement. |
| Q36678894 | Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants |
| Q53906979 | Cardiovascular disease prevention in postmenopausal women: a clinician's perspective. |
| Q73388151 | Cardiovascular responses of perimenopausal women to hormonal replacement therapy |
| Q71816404 | Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol |
| Q45237517 | Cardiovascular risk factors in middle-aged women and the association with use of hormone therapy: results from a population-based study of Swedish women. The Women's Health in the Lund Area (WHILA) Study |
| Q73550783 | Changes in atherogenic lipids and lipoproteins during natural and hyperstimulated cycles in healthy women |
| Q61387330 | Changes in plasma lipids and lipoproteins associated with starting or stopping postmenopausal hormone replacement therapy |
| Q34326838 | Chemotherapy-induced menopause: a literature review |
| Q89585086 | Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy |
| Q40442998 | Clinical Pharmacology of Estrogens: Cardiovascular Actions and Cardioprotective Benefits of Replacement Therapy in Postmenopausal Women |
| Q53979884 | Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy. |
| Q33579316 | Current and potential future drug treatments for osteoporosis |
| Q43267040 | Current state of hormone replacement therapy: the case for using trimegestone |
| Q34139451 | DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women |
| Q43028516 | DHEA, important source of sex steroids in men and even more in women |
| Q68179274 | Disparate serum lipid changes between normotensive and hypertensive women during the menstrual cycle |
| Q46663337 | Does body mass index, smoking, lipoprotein levels, surgically induced menopause, hormone replacement therapy, years since menopause, or age affect hemostasis in postmenopausal women? |
| Q40802343 | Dyslipoproteinemia in women and the elderly. |
| Q36836880 | Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II. |
| Q74449516 | Effect of naturally reduced ovarian function on plasma lipoprotein and 27-hydroxycholesterol levels in baboons (Papio sp.). |
| Q44203348 | Effect of tibolone administration on heart rate variability and free fatty acid levels in postmenopausal women |
| Q44431632 | Effects of Hormone Replacement Therapy on Circulating Docosahexaenoic Acid and Eicosapentaenoic Acid Levels in Postmenopausal Women |
| Q44223636 | Effects of age, hypertension and HRT on serum aminopeptidase A activity |
| Q43612137 | Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy |
| Q73807090 | Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women |
| Q73928098 | Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy |
| Q78016942 | Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group |
| Q35042165 | Enhanced relaxation of porcine coronary arteries after acute exposure to a physiological level of 17beta-estradiol involves non-genomic mechanisms and the cyclic AMP cascade. |
| Q71598016 | Estradiol-17beta as an antioxidant: some distinct features when compared with common fat-soluble antioxidants |
| Q39434008 | Estradiol-delivering vaginal rings for hormone replacement therapy |
| Q50529691 | Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. |
| Q40747941 | Estrogen replacement therapy in women at increased risk for breast cancer |
| Q34447831 | Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women |
| Q43814234 | Estrogen/progesterone replacement versus pravastatin and their sequential association in hypercholesterolemic postmenopausal women |
| Q73742775 | Fibrinogen and plasminogen modifications during oral estradiol replacement therapy |
| Q61795332 | HDL-cholestérol et approche thérapeutique |
| Q57658344 | HDL-cholestérol et risque cardiovasculaire : au-delà du LDL ! |
| Q39490443 | HRT and osteoporosis |
| Q34407513 | HRT in women with diabetes--review of the effects on glucose and lipid metabolism |
| Q36144161 | Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature. |
| Q34145809 | Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment |
| Q77571421 | Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease |
| Q78051143 | Hormone replacement therapy in postmenopausal women: carotid intima-media thickness and 3-D volumetric plaque quantification |
| Q39467095 | Hormone replacement therapy in the aged. A state of the art review |
| Q71380555 | Hormone replacement therapy modifies the capacity of plasma and serum to regulate prostacyclin and endothelin-1 production in human vascular endothelial cells |
| Q55502365 | Impact of green tea extract on serum lipid of postmenopausal women: A randomized controlled trial. |
| Q51594762 | Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women. |
| Q44875353 | Impact of subdermal norgestrel on hepatic acyl-coenzyme A:cholesterol- acyltransferase (ACAT) activity: possible antiatherogenic effect |
| Q39861823 | Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study |
| Q74310135 | Increased activity of lecithin:cholesterol acyltransferase during short-term oral estrogen progestin replacement therapy in a group of postmenopausal women |
| Q57664322 | Influências da reposição de estrógenos e progestágenos na ação do hormônio de crescimento em mulheres com hipopituitarismo |
| Q36535984 | Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study. |
| Q44604661 | Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen |
| Q44454518 | Menopause rather than estrogen modifies plasma homocysteine levels. |
| Q44093037 | No antioxidant effect of combined HRT on LDL oxidizability and oxidative stress biomarkers in treated post-menopausal women |
| Q58294084 | Oestrogen replacement therapy and coronary heart disease |
| Q40877161 | Oestrogens and atherosclerotic vascular disease--lipid factors |
| Q33700669 | Pharmacokinetics of raloxifene and its clinical application |
| Q43612141 | Phenotype of apolipoprotein E influences the lipid metabolic response of postmenopausal women to hormone replacement therapy |
| Q40458696 | Postmenopausal Hormone-Replacement Therapy and Cardiovascular Risk |
| Q40390669 | Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review. |
| Q33668351 | Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden |
| Q73179490 | Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat |
| Q40790328 | Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein |
| Q34236652 | Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities |
| Q33703846 | Raloxifene, a new selective estrogen receptor modulator |
| Q71843113 | Regression of Atherosclerosis in Female Monkeys |
| Q40814818 | Relative value of transdermal and oral estrogen therapy in various clinical situations |
| Q48908588 | Risk factors for brain infarction in patients with Cushing's disease. Case reports |
| Q33786237 | Screening for cardiovascular disease. Concepts, conflicts, and consensus |
| Q44752125 | Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy |
| Q40503556 | Should high lipid levels in very old patients be lowered? |
| Q33992554 | Soy protein in the management of hyperlipidemia |
| Q35855883 | The cardiovascular effects of chronic hypoestrogenism in amenorrhoeic athletes: a critical review. |
| Q33845784 | The effect of hormone replacement therapy and exercise on cardiovascular disease risk factors in postmenopausal women |
| Q73477000 | The effect of hormone replacement therapy on metabolism of lipoprotein remnants in postmenopausal women |
| Q46515516 | The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women |
| Q47608664 | The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women |
| Q47102333 | The effects of progesterones on blood lipids in hormone replacement therapy |
| Q33814554 | The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers |
| Q39462339 | The menopause and the cardiovascular system |
| Q58265908 | The relationship between plasma androgens (dehydroepiandrosterone sulfate and testosterone) and coronary arteriosclerosis in men: The lower the androgens, the higher the coronary score of arteriosclerosis |
| Q34238238 | The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives |
| Q44064676 | The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. |
| Q50858972 | Wellness in women after 40 years of age: the role of sex hormones and pheromones. |
| Q40838703 | Women, dyslipoproteinemia, and estrogens |
| Q52897432 | [Estrogens for prevention of coronary heart disease?]. |